Contributing to Global Healthcare Through Cutting-Edge Antibody Technologies
First written in FY2021. 13 of 14 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our antibody generation platform.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, based on its antibody generation platform. - FY2025RestatedAnnual report
「Our basic policy is to contribute to global healthcare by advancing the research and development of therapeutic antibody drugs for cancer and other diseases, leveraging the protein expression technology developed at LSBM, antibody screening technology using phage antibody libraries, and seed discovery technology.」
The company has reaffirmed its basic policy of contributing to global healthcare by using cutting-edge antibody technology to research and develop therapeutic antibody drugs for cancer and other diseases. - FY2025-H1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our antibody generation platform.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, by leveraging its antibody generation platform. - FY2024-Q2RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, by leveraging its efficient antibody generation platform. - FY2024-Q1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, based on its efficient antibody generation platform. - FY2023RestatedAnnual report
「Our basic policy is to contribute to global healthcare by advancing the research and development of therapeutic antibody drugs for cancer and other diseases, leveraging the protein expression technology developed at LSBM, antibody screening technology using phage antibody libraries, and seed discovery technology.」
The company has reaffirmed its basic policy of contributing to global healthcare by using cutting-edge antibody technology to research and develop therapeutic antibody drugs for cancer and other diseases. - FY2023-Q3RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, by leveraging its efficient antibody generation platform. - FY2023-Q2RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform.」
The company has reaffirmed its policy of advancing antibody development, primarily in the oncology field, by leveraging its efficient antibody generation platform. - FY2023-Q1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, based on its efficient antibody generation platform. - FY2022RestatedAnnual report
「Our basic policy is to contribute to global healthcare by advancing the research and development of therapeutic antibody drugs for cancer and other diseases, leveraging the protein expression technology developed at LSBM, antibody screening technology using phage antibody libraries, and seed discovery technology.」
The company has reaffirmed its basic policy of contributing to global healthcare by using cutting-edge antibody technology to research and develop therapeutic antibody drugs for cancer and other diseases. - FY2022-Q3RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform to address unmet medical needs.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, based on its efficient antibody generation platform. - FY2022-Q2RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform to address unmet medical needs.」
The company has reaffirmed its policy of advancing antibody development, primarily in the oncology field, based on its efficient antibody generation platform. - FY2022-Q1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform to address unmet medical needs.」
The company has reaffirmed its basic policy of advancing antibody development, primarily in the oncology field, based on its efficient antibody generation platform. - FY2021First statedAnnual report
「Our basic policy is to contribute to global healthcare by advancing the research and development of therapeutic antibody drugs for cancer and other diseases, leveraging the protein expression technology developed at LSBM, antibody screening technology using phage antibody libraries, and seed discovery technology.」
The company has stated its basic policy of advancing the research and development of therapeutic antibody drugs for cancer and other diseases, based on technology originating at the University of Tokyo and antibody discovery technology.